share_log

Clene | 10-K: FY2023 Annual Report

Clene | 10-K: FY2023 Annual Report

Clene | 10-K：2023財年年報
美股SEC公告 ·  03/13 07:53
Moomoo AI 已提取核心訊息
Clene Inc., a clinical-stage pharmaceutical company, reported its annual financial results, highlighting a 38% increase in total revenue from $473,000 in 2022 to $654,000 in 2023. This growth was driven by a 51% rise in product revenue and an 8% increase in royalty revenue. Despite this, the company experienced a 16% decrease in operating expenses, primarily due to reduced research and development costs, which fell from $31.92 million to $26.655 million. General and administrative expenses also decreased by 15%. However, Clene Inc. reported a net loss of $49.504 million, a 65% increase from the previous year's $29.918 million loss. The company has not yet achieved profitability and has no drugs approved for commercial sale. Clene Inc. continues to focus on developing its novel clean-surfaced nanotechnology (CSN®) therapeutics, with multiple drug assets in development and clinical trials, primarily for neurology applications. The company's future plans include initiating an international Phase 3 study of CNM-Au8 30 mg, RESTORE-ALS, in the second half of 2024, contingent upon funding, and further engagement with the FDA to support potential approval of their drug candidates.
Clene Inc., a clinical-stage pharmaceutical company, reported its annual financial results, highlighting a 38% increase in total revenue from $473,000 in 2022 to $654,000 in 2023. This growth was driven by a 51% rise in product revenue and an 8% increase in royalty revenue. Despite this, the company experienced a 16% decrease in operating expenses, primarily due to reduced research and development costs, which fell from $31.92 million to $26.655 million. General and administrative expenses also decreased by 15%. However, Clene Inc. reported a net loss of $49.504 million, a 65% increase from the previous year's $29.918 million loss. The company has not yet achieved profitability and has no drugs approved for commercial sale. Clene Inc. continues to focus on developing its novel clean-surfaced nanotechnology (CSN®) therapeutics, with multiple drug assets in development and clinical trials, primarily for neurology applications. The company's future plans include initiating an international Phase 3 study of CNM-Au8 30 mg, RESTORE-ALS, in the second half of 2024, contingent upon funding, and further engagement with the FDA to support potential approval of their drug candidates.
臨床階段藥品公司Clene報告稱，其年度財務業績表現良好，總營業收入自2022年的473,000美元增長38%至2023年的654,000美元。這種增長的推動力來自產品銷售收入增長51%和版稅收入增長8%。儘管如此，由於研發成本降低，從3192萬美元下降到2665.5萬美元，公司的營業費用下降了16%。總部和行政費用也減少了15%。然而，Clene報告淨虧損4950.4萬美元，比前一年的2991.8萬美元虧損增加了65%。該公司尚未實現盈利，並且沒有獲得商業銷售批准的藥品。Clene繼續專注於開發其具有創新性的納米技術(CSN®)治療方案，擁有多種藥品資產正在開發和進行臨床試驗，主要用於神經學應用。該公司未來計劃包括在2024年下半年開始進行CNm-Au8 30毫克的國際3期研究RESTORE-ALS（如獲得資金支持），並進一步與FDA合作支持其藥品候選人的潛在批准。
臨床階段藥品公司Clene報告稱，其年度財務業績表現良好，總營業收入自2022年的473,000美元增長38%至2023年的654,000美元。這種增長的推動力來自產品銷售收入增長51%和版稅收入增長8%。儘管如此，由於研發成本降低，從3192萬美元下降到2665.5萬美元，公司的營業費用下降了16%。總部和行政費用也減少了15%。然而，Clene報告淨虧損4950.4萬美元，比前一年的2991.8萬美元虧損增加了65%。該公司尚未實現盈利，並且沒有獲得商業銷售批准的藥品。Clene繼續專注於開發其具有創新性的納米技術(CSN®)治療方案，擁有多種藥品資產正在開發和進行臨床試驗，主要用於神經學應用。該公司未來計劃包括在2024年下半年開始進行CNm-Au8 30毫克的國際3期研究RESTORE-ALS（如獲得資金支持），並進一步與FDA合作支持其藥品候選人的潛在批准。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

獨立文件9  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息